Business Wire

CT-STARWOOD-HOTELS

29.4.2016 12:11:17 CEST | Business Wire | Press release

Share
An Indie Darling: Tribute Portfolio Sees Impressive First Year, Doubling Growth Projections and Reaching 20 Hotels Globally

Tribute Portfolio, a collection of independent hotels and resorts from Starwood Hotels & Resorts Worldwide, Inc. (NYSE: HOT), today announced three new signings, bringing the brand’s footprint to 20 properties worldwide, exactly double the original growth projection for its first year. Continuing to global expansion with its first-ever property in China and continuing to expand in Florida with signings in Tampa and Sarasota, Tribute Portfolio maintains its steadfast position as having the fastest takeoff of any Starwood brand, ever, while also celebrating its individuality through innovative social media and brand partnership strategies. With a long runway to grow, Tribute Portfolio continues to add exceptional properties around the globe that offer guests and owners the ability to “Stay Independent.”

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160429005399/en/

From the Bustling City of Shanghai to the Sunny Coast of Florida

With momentum steadily building for the one year old brand, Tribute Portfolio once again answers consumer demand with the addition of three properties in Shanghai, Sarasota and Tampa. When surveying Starwood Preferred Guest® (SPG) Members, the brand found that 62% would be very interested in staying at a Tribute Portfolio hotel in Shanghai. Answering this call, Tribute Portfolio will expand its footprint in Asia by adding a property in the cosmopolitan Chinese city. Members also told the brand that beach destinations remain at the top of their list, particularly in Florida. As a result, the brand will open an additional two new properties in the Sunshine State: a 323-room hotel in Tampa, and The Sarasota Modern, a Tribute Portfolio Hotel, in Sarasota.

Giving Guests -- And Owners -- What They Want

From boutique resorts to urban destination properties, Tribute Portfolio gives guests access to outstanding upper upscale hotels with an independent spirit, all while benefitting from the award-winning SPG® program. Built and fueled by consumer preferences, Tribute Portfolio carves out its distinction in the category through its close collaboration with the SPG community.

“The independent hotel segment has continued to grow exponentially, with consumers increasingly desiring travel to hotels and resorts that don’t fall under a cookie-cutter brand,” said Dave Marr, Global Brand Leader, Tribute Portfolio. “This trend, coupled with the strength and support of our owner and developer community, has contributed to the meteoric growth of the brand and its continued success as we enter our second year.”

Tribute Portfolio debuted in April 2015 with its first hotel, the Royal Palm South Beach Miami, and has since opened eight additional properties: the Great Northern Hotel in London, UK; The Kiroro Resort in Hokkaido, Japan; The Hermitage in Jakarta, Indonesia; the SLS Las Vegas in Las Vegas, NV; The Riviera Palm Springs in Palm Springs, CA; Avenue of the Arts in Costa Mesa, CA; and Le Dokhan’s and Le Metropolitan, both in Paris. Future locations include Coral Gables, FL; Fort Lauderdale, FL; Tampa, FL; Sarasota, FL; Asheville, NC; Nashville, Tennessee; Savannah, GA; Charleston, SC; Denver, CO; Shanghai, China; and Quebec City, Canada.

With flexibility and individuality at its core, Tribute Portfolio has also struck a chord with the owner/developer community, enabling them to maintain their independent spirit, while benefiting from Starwood's powerful distribution, loyalty and sales platforms.

"The rapid rate of growth that Tribute Portfolio has achieved comes as no surprise, combining Starwood’s robust sales, marketing and loyalty programs with the flair and individualism of the independent boutique hotelier,” said Jeremy Robson, Owner-Operator, Great Northern Hotel, London. “I am delighted that Great Northern Hotel is now part of the Tribute Portfolio franchise, and the abundant positive feedback we get from our customers indicates they feel the same. I expect the brand’s global expansion to continue accelerating way beyond the most optimistic of forecasts.”

Reaching Socially Connected, Independent-Minded Travelers

Shifting focus from being the expert on the destination, Tribute Portfolio instead elevates the notion that guests seek out independent hotels because the hotels themselves can be the destination. To capture this, each Tribute Portfolio property features a noteworthy selection of #independentmoments : distinct design details and experiences that illustrate what guests love about “staying independent.” In addition, Tribute Portfolio is the first hotel brand to partner with consumer shopping service, LIKEtoKNOW.it , enabling travelers to translate their wanderlust into room bookings at two of the Tribute Portfolio brand’s newest hotels – Le Metropolitan and Le Dokhan’s – directly by “liking” a photo on Instagram. Finally, the brand also launched a new partnership with Pitchfork that will bring unique pop-up music activations to several Tribute Portfolio properties worldwide, exposing guests to emerging artists and established pioneers who apply a true independent mindset to their musical craft, regardless of genre.

For more information, please visit www.tributeportfolio.com .

# # #

About Tribute Portfolio
Launched in April 2015 as Starwood’s 10th brand and second collection of independent hotels, Tribute Portfolio is comprised of exceptional independent hotels around the globe, offering guests and owners the ability to “Stay Independent.” From boutique resorts to urban destination properties, guests can enjoy access to outstanding upper upscale hotels with an indie spirit while benefitting from the award-winning Starwood Preferred Guest (SPG) program. For more information on Tribute Portfolio, please visit www.tributeportfolio.com . Follow along to Stay Independent: @TributePortfolio on Instagram, @TributePRTFLO on Twitter, tumblr.com/TributePortfolio and www.facebook.com/TributePortfolio .

Contact:

Starwood Hotels & Resorts
Media Contacts
Julien Guitard, +32 2 204 5160
Associate Director Communications – Europe, Africa & Middle East
Julien.Guitard@starwoodhotels.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye